Catalent Pharma Solutions, the firm born from the spin out of
Cardinal Health's contract manufacturing business, is reorganising
its production facilities with an expansion of its UK site and the
divestiture of some of its French...
Cardinal Health is about to sell its drug manufacturing arm to an
international private investment firm, only two months after
announcing its decision to divest the segment, while its second
quarter earnings doubled as a result.
Cardinal Health has announced the results of its radiofrequency
identification (RFID) tag pilot, the first to test the viability of
the technology across the whole supply chain, from item through to
case and pallet level.
Cardinal Health has taken the contract manufacturing crown after
being honoured with a prestigious award from Frost & Sullivan
in recognition of its ability to provide biopharma firms with a
high quality service, while still remaining...
Cardinal Health posted higher earnings in the first quarter of
fiscal 2004, on the back of increased demand in its prescription
drug wholesale business but also some impressive gains at its
pharmaceutical technologies activities....
US outsourcing company Cardinal Health is to provide alternative
drug formulation development and delivery capabilities for the
biotechnology and pharmaceutical industries, the company announced